Skip to main content

Day: June 14, 2024

Form 8.3 – [TRIDENT ROYALTIES PLC – Opening Disclosure – 13 06 2024] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree TRIDENT ROYALTIES PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Form 8.3 – [LOK’N STORE GROUP PLC – 13 06 2024] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LOK’N STORE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Form 8.3 – [MATTIOLI WOODS PLC – 13 06 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree MATTIOLI WOODS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: MATTIOLI WOODS PLC AS AN ASSOCIATE...

Continue reading

Form 8.3 – [KEYWORDS STUDIOS PLC – 13 06 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree KEYWORDS STUDIOS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Bioanalytical Testing Services Market will Reach USD 8.51 Billion by 2031 | SkyQuest

Westford USA, June 14, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Bioanalytical Testing Services Market will attain a value of USD 8.51 Billion by 2031, with a CAGR of 15% over the forecast period (2024-2031). The main reason behind the growth of this market is the recent tendency by major pharmaceutical firms to subcontract out their research and development (R&D) activities so they can focus on their main competencies. Additionally, during the estimated period, there will be high demand levels as it is cheaper when a study is done outside other than internally. It is anticipated that innovation and the creation of new products will increase demand for these services even more. Companies are outsourcing these services due to pressure from the competition and pricing concerns. Download a detailed overview: https://www.skyquestt.com/sample-request/bioanalytical-testing-services-market Browse...

Continue reading

Rail Vision Installed its AI-Driven Product with Loram, a Top US-Based Railway Track Maintenance Supplier

Ra’anana, Israel, June 14, 2024 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, today announced the successful delivery and installation of its AI-driven Shunting Yard product to Loram, a leading US-based provider of railway track maintenance equipment and services. This installation fulfills the purchase order announced on April 3, 2024, and marks the beginning of a pilot project aimed at enhancing Loram’s rail track maintenance operations with Rail Vision’s advanced technology. Pending a successful pilot completion, the two companies will consider an expansion of this product, further integrating Rail Vision’s innovative solutions into Loram’s rail vehicles across the United States. The Shunting...

Continue reading

McEwen Mining Announces Closing of Flow-Through Financing

TORONTO, June 14, 2024 (GLOBE NEWSWIRE) — McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) (“McEwen”) is pleased to report it has closed the previously announced public financing for US$22.0 million (Cdn$30.0 million) to fund ongoing exploration and development at the Fox Complex in the Timmins region of Ontario, primarily focused on exploration drilling and the development of an underground access ramp from surface to mine the gold resources of Stock East and West. This represents the next area of production growth at the Fox Complex. The proceeds of this financing will be used exclusively for qualifying Canadian Exploration Expenses (within the meaning of subsection 66.1(6) of the Income Tax Act (Canada)) (“CEE”) and Canadian Development Expenses (within the meaning of subsection 66.2(5) of the Income Tax Act (Canada)) (“CDE”), including: Part...

Continue reading

OneMedNet Partners with Leading Clinical Trial Design and Software Company in Significant Data License Agreement

Partner’s software products and services are utilized by hundreds of life science organizations, including the top 30 biopharmaceutical companies MINNEAPOLIS, June 14, 2024 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (“RWD”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, announced today that it has entered into a iRWD™ Customer Data License (the “Agreement”) with an undisclosed U.S.-based global leader in clinical trial design and software. Pursuant to the Agreement, OneMedNet will utilize its proprietary iRWD™ platform to securely search, de-identify and curate current, regulatory-grade clinical data for the new customer, including its world-wide subsidiaries and affiliates,...

Continue reading

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025 Poster presentation today at 14:45 CET / 8:45 a.m. ET  BOSTON, June 14, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, being held June 12-15 in Vienna, Austria. The data demonstrated that in a collagen-induced arthritis (CIA) murine model, oral dosing of MRT-6160 inhibited disease...

Continue reading

Big Data Analytics Market to Excel USD 845.97 Billion by 2031 | SkyQuest

Westford USA, June 14, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Big Data Analytics Market will attain a value of USD 845.97 Billion by 2031, with a CAGR of 13.40% over the forecast period (2024-2031). Advanced big data analytics, which help enterprises comply with current platform-based models while keeping important information, allow the roles associated with performance monitoring and expenditure containment to be executed with greater efficiency on a larger scale, once data have been sent for storage. Furthermore, advanced analytics projects comprising learning applications, predictive analysis, and data mining are the main uses of the expanding, large data ecosystem. It therefore offers more flexibility for data processing, collecting, and analysis than conventional database systems such as data warehouses and relational...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.